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Colon carcinoma is one of the most common malignant tumours and the second 
cause of cancer deaths in developed countries. 
The objective of this study is to investigate the expression of HER2 in colorectal 
cancer and compare the expression levels of HER2 with the macroscopic appearance and 
manner of growth of the tumours, followed by detection and identification of the 
expression levels of proto-oncogene HER2 as an important prognostic factor of the 
further course, outcome and the data for the selection of appropriate therapy. 
This was a prospective, clinical and experimental study. Postoperative material 
obtained by resection of colorectal cancer from 63 patients of both sexes was used in 
the study.  
HER2 status was positive in 9.5% of the tumours. The results showed that the 
majority of tumours 36/63, i.e. 57.1% were manifested as infiltrative forms, 9/63, i.e. 
14.3% as ulcerating form, and 18/63, i.e. 28.6% of tumours had a polypoid – exophytic 
form. The results show that 31 tumours of infiltrative forms were HER2 negative and 5 
of them were HER2 positive. In tumours with ulcerating form 9 were HER2 negative, and 
t h e r e  w e r e  n o  H E R 2  p o s i t i v e  t u m o u r s .  I n  v e g e t a t i v e  t u m o u r  f o r m s  1 7  w e r e  H E R 2  
negative, and only 1 was HER2 positive. 
HER2 expression was absent in 90.5% of the tumours and does not correlate with 
the macroscopic appearance and manner of tumour growth. Expression level of HER2 
does not have a diagnostic, predictive and prognostic potential, while its importance is 
undeniable in the understanding of oncogenesis. Acta Medica Medianae 2011; 50(4):5-10. 
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Introduction 
 
Colon carcinoma is one of the most common 
malignant tumours and the second cause of cancer 
deaths in developed countries (1).  
Processes of division, differentiation and 
cell death are strictly controlled, and a disorder in 
the regulation of any of them gives rise to clones 
of cells that independently and inappropriately 
breed and produce tumour mass. Onset of 
tumour is a complex process involving many 
genetic and molecular mechanisms. Oncogenesis 
is the result of accumulation of disorder in the 
structure and function of genes regulating cell 
proliferation mechanisms, reparation of DNA 
molecule or programmed cell death. These genes 
are: oncogenes, tumour suppressor genes, genes 
that are the matrix for the synthesis of the 
reparatory system enzymes, as well as genes 
that control apoptosis (2). 
The human genome has a normal presence 
of proto-oncogenes, whose protein products 
participate in the transmission of signals that 
control cell proliferation. Mutated protooncogenes 
are oncogenes and their products are oncoproteins 
(3), and via receptors and soluble factors that 
bind to them, a cell communicates with the 
environment, and disturbances in the transmission 
of signals from cell membrane to the nucleus can 
lead to changes of mitotic activity or the ability of 
differentiation (4). HER 2 (human epidermal growth 
factor receptor) from the EGFR family is a 
transmembrane, glycoprotein receptor gene 
which is encoded by a gene on the chromosome 
17. In terms of cell transformation - modified 
physiological structures and functions in regards 
of control of cell cycle and death, increased 
expression classifies HER 2 as an oncoprotein (5). 
Ligand for HER2 has not yet been 
identified, but it is considered that this molecule Correlation of HER 2 proto-oncogene expression with the...                                                                       Jelena Lukić-Flora et al. 
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belongs to HRG (heregulin) family. HRG and 
HER2 genes are genes that are most spliced i.e. 
with the most exons and introns, which means 
they have lots of protein forms (isoforms). 
Members of the EGFR and HER family are 
bivalent and thus HER family receptors homo-and 
hetero-dimerize, binding themselves to different 
isoforms of the ligand, thus creating a specific 
network of signal transduction through the cell, 
because each combination of receptor-ligand has 
their own way of signal transmission through the 
cell. This further modifies the expression of genes 
that change cell phenotype and function in terms 
of changed presentation of molecules on the 
surface of cells and synthesis of specific proteins 
(6-8). The result of hyperactivity of these 
signalling pathways through the cell, leads to 
expression and activation of proteins that lead to 
the development of the cell cycle and prevention 
of cell death. Wrong expression of any enzyme or 
protein from the signal transmission cascade 
through the cell is sufficient to affect the balance 
of development control of cell cycle and apoptosis. 
There are several morphological types of 
colorectal cancer: a ring (annular), vegetative 
(polypoid), infiltrative and ulcerating tumours (9). 
On the left side the majority of colorectal 
cancers are ringed lesions that significantly 
narrow the lumen, and consequently often cause 
expansion of proximal intestine. The edges of the 
ring are raised and firm, while the central part is 
usually ulcerated. These tumours over time (in 
years) penetrate the bowel wall and can occur as 
sub-serous or serous, a solid whitish thickening. 
Their metastases spread to regional lymph nodes 
and liver, and later distant organs (9,10). 
Right colon cancers are generally polypoid, 
with mushroom-like appearance and protrude 
into the lumen like "cauliflower" masses. These 
lesions are rarely ulcerative type or in the form of 
plaque. Regardless of the macroscopic appearance, 
these tumours penetrate the bowel wall and 
spread to mesentery and regional lymph nodes. 
It is possible that they further disseminate in the 
liver and other organs (9-11). 
The aim of this study was to examine the 
expression of HER2 at the operational material-
resectioned segment of patients with colorectal 
cancer, comparing the expression levels of HER 2 
with the macroscopic appearance and manner of 
tumour growth, identification of possible prognostic 
significance of this correlation, and the detection 
and identification of HER2 expression levels as an 
important prognostic factor in the further course 
of illness and the data for the choice of suitable 
and individual antitumor therapy. 
 
Material and methods 
 
This was a prospective, clinical and experi-
mental study. Postoperative material obtained by 
resection of the colorectal tumours of 63 patients 
of both sexes was used, from the Surgery Clinic 
of the Clinical Centre "Kragujevac", in Kragujevac. 
I n  o r d e r  t o  o b t a i n  a s  m u c h  r e l e v a n t  h i s t o -
pathological data, the routine hematoxylin - eosin 
(HE) and immunohistochemical methods were 
performed at the Centre for the pathological-
anatomical diagnosis of CC "Kragujevac", Kragujevac.  
Routine HE method was used for patho-
histological verification of tumours, and histo-
pathological analysis. In the routine processing of 
products, tissue samples were fixed in 4% neutral 
buffer formalin solution, in 24 hours, at room 
temperature. Upon completion of fixation, they 
were dehydrated through a series of alcohols of 
increasing concentration (70%, 96% and 100%), 
stained in xylol and embedded in paraffin. Tissue 
sections, 4 μm thick, were cut with microtomes 
Leica SM 2000R and Leica Reinhart Austria.   
After deparaffinization in xylol and hydration 
in decreasing order of alcohol, sections were 
stained with haematoxylin according to Mayer, 
stained in 2% eosin, then dehydrated, stained 
and mounted on a plate with Canada balsam (12-
14). 
Immunohistochemical methods were used 
to identify the expression of antigen in colorectal 
cancer resection sample. The procedure for immuno-
histochemical staining included the unmasking of 
antigens, blocking of endogenous peroxidase, 
incubation with primary antiserum preparation and 
the procedure of immuno-histochemical methods - 
LSAB+ - HRP (15).  
Evaluation of HER2 expression results was 
performed according to the criteria recommended 
by the manufacturer („DAKO - Hercep Test”). The 
estimate is based on the determination of three 
parameters: the percentage of tumour cells whose 
membranes show immunoreactivity (limit is 10%), 
of continuity, i.e. discontinuity and intensity of 
immunoreactive staining of the membrane. 
Immunological criteria for the assessment of 
HER2 expression: 
0 – no staining or membrane staining is at 
least 10% of tumour cells 
1+ - barely stained membrane in more 
than 10% of tumour cells 
2+ - weak or intermediate staining of the 
entire membrane in more than 10% of tumour 
cells  
3+ - strong staining of the entire membrane 
in more than 10% of tumour cells 
0 and 1 + are the negative result of a 2 + 
and 3 + are the positive results 
Cytoplasmic expression was not included in 
the assessment of positivity. 
Immunohistochemical staining was carried 
out with the control of quality and specificity of 
staining, using positive and negative controls 
according to the propositions of UK NEQAS (UK 
National External Quality Assessment for immuno-
cytochemistry). For statistical data processing the 
SPSS software package and methods of descriptive 
statistics were used (frequencies, percentages, 
medians, percentiles). Analysis of two descriptive 
variables was carried out using Chi-square test 
and Fisher test. Investigation of the effect of 
several variables on a binary variable was per-
formed using binary logistic multivariant regression.  Acta Medica Medianae 2011, Vol.50(4)                                                 Correlation of HER 2 proto-oncogene expression with the... 
Results 
 
The largest number of tumours 36/63, i.e. 
57.1% was manifested in the form of infiltrative 
forms, 9 / 63, i.e. 14.3% as ulcerating form, and 
18/63, i.e. 28.6% of tumours had a polypoid - 
exophytic appearance (Table 1). 
Expression of HER2 was present in 57/63, 
i.e. 90.5% of tumours. HER2 status was positive 
in 6 / 63, i.e. 9.5% of tumours, i.e. demonstrated a 
continuous membrane immunoreactivity of moderate 
and high intensity (more than 10% tumour 
cells) (Table 2, Figure 1). 
 
Figure 1: HER2 expression 
 
Table 1. Macroscopic manifestation of tumour 
 
Macroscopic 
manifestation of 
tumour 
Frequency Percentage  (%) 
Vegetative 18  28,6 
Ulcerating 9  14,3 
Infiltrative 36  57,1 
Total 63  100,0 
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Table 2. HER2 expression 
 
HER-2 expression  Frequency  Percentage (%) 
Negative 57  90,5 
Positive 6  9,5 
Total 63  100,0 
 
Table 3. Correlation between macroscopic manifestation 
of tumour and HER2 
 
Macroscopic 
manifestation 
of tumour 
HER2- HER2+  Percentage 
(%) - 
Percentage 
(%) + 
Vegetative 
form  17 1 94.44  5.56 
Ulcerating 
form  9 0  100  0 
Infiltrative 
form  31 5 86.11 13.89 
 
The results showed that 31 infiltrative form 
tumours were HER2 negative and 5 of them were 
HER2 positive. In tumours of ulcerating form 9 
were HER2 negative, and there were no positive 
HER2 tumours. Vegetative forms tumours had 17 
HER2 negative, and only 1 was HER2 positive 
(Table 3). 
Macroscopic manifestation of the tumour 
and HER2 are independent (p=1.355). 
In order to obtain reliable parameters to 
examine the various factors that could affect the 
expression of HER2, binary logistic regression 
was performed.  
The presented results showed that HER2 is 
not dependent on clinical and histological parameters 
(Figures 2-5). 
 
 
 
 Figure 2: HER2 – negative internal control (IHH,x 200) 
 
 
 
Figure 3: HER 2=1, weak staining of the entire 
membrane of more than 10% of tumour cells(IHH x 200) 
 
 
 
Figure 4: HER2=2+, moderate staining of the entire 
membrane of more than 10% of tumour cells (IHH x 400) Correlation of HER 2 proto-oncogene expression with the...                                                                       Jelena Lukić-Flora et al. 
The results of this study showed expression 
in 9.5% of the tumours, where the range of HER2 
expression is from 0 to 85% in the available 
literature, which correlates with the results pre-
sented (20). However, the same literature shows 
contradictory results that were obtained when 
another method was applied for determining 
HER2 status (Hercept Test - kit (DAKO, Glostrup, 
Denmark)), which suggests that a methodology 
could affect the obtained expression result. 
 
Research shows that only ¼ of patients 
with HER2 overexpression has a favourable 
response to treatment with Herceptin. The goal is 
to determine the potentials role of this drug, as 
there are valid methods for detection of patients 
with CRC. This result is a consequence of lack of 
standardized methods, types of antibodies, the 
tissue used, inadequate storage and cytoplasmic 
presentation of HER2, which is not targeted by 
Herceptin. FISH uses more objective scoring, 
sensitivity of 96% and specificity 100%. IHH is 
cheaper, more available and requires routine 
microscopy. FISH is an expensive method, which 
requires fluorescent microscopy and has difficulty 
distinguishing tumour cells from the stroma (21). 
 
Figure 5: HER2=3+, more than 10% tumour cells showing 
high intensity continuous immunoreactivity (IHH x 200) 
 
Discussion 
 
Colorectal cancer (CRC) is one of the most 
common causes of morbidity and mortality in the 
western world and in our region. Classifications 
and established prognostic parameters, which are 
used in the treatment of CRC still only partially 
provide information about the course and 
outcome of this disease; hence, there is a need 
to improve the existing and identify new diag-
nostic and prognostic markers. In this regard, it 
is especially important to identify molecular 
markers that would provide insight into the 
potential behaviour or aggressiveness of the 
tumours (16-18). 
HER2 expression does not depend on the 
macroscopic manifestations of tumours and tumour 
growth pattern, i.e., there is no correlation between 
HER2 expression and the macroscopic manife-
station and manner of growth of CRC, which 
would serve as a prognostic factor in the further 
course and outcome of the illness. 
  
Conclusion  
 
Since the current clinical and morphologic 
parameters (histological type of tumour, degree 
of differentiation, tumour stage, nodal status, 
invasion of vascular structures and surgical 
margins) still retain their dominant role in 
diagnostic procedures, molecular profiling will 
contribute to their completion, usually in terms 
of recognition of response to applied therapy 
(genetic changes), or in terms of improving the 
screening of high-risk categories to allow for 
timely and successful treatment (19). 
Expression of HER 2 was absent in 90.5% 
of the tumours and does not correlate with the 
macroscopic manifestation or the growth pattern 
of colorectal carcinoma.  
From all the foregoing, it can be concluded 
that previous studies have not demonstrated the 
role of HER 2 as an important prognostic indicator. 
Evaluation of the genes and molecular profiling 
can help identify groups of patients with HER 2 
overexpression, which could imply a particular 
therapeutic intervention and an important screening 
for target therapeutic purposes.   The largest number of tumours 36/63, i.e. 
57.1% was manifested in the form of infiltrations, 
9 / 63, i.e. 14.3% as ulcerating form, and 18/63, 
i.e. 28.6% of tumours had a polypoid – exophytic 
look.  
An expression level of HER 2 has diagnostic, 
predictive and prognostic potential, while its 
importance is undeniable in the understanding of 
oncogenesis.   
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KORELACIJA EKSPRESIJE HER 2 PROTOONKOGENA SA 
MAKROSKOPSKOM MANIFESTACIJOM I NAČINOM RASTA 
KOLOREKTALNIH KARCINOMA 
 
Jelena Lukić-Flora, Dušica Petrović, Vesna Stanković, Miloš Milosavljević i 
Vladimir Bulatović 
 
 
Karcinom debelog creva jedan je od najčešćih malignih tumora i drugi po redu   
uzročnik smrti od karcinoma u razvijenim zemljama. 
Cilj istraživanja bilo je ispitivanje ekspresije HER2 kod kolorektalnog karcinoma kao 
i komparacija nivoa ekspresije HER2 sa makroskopskim izgledom i načinom rasta 
tumora, zatim detekcija i identifikacija nivoa ekspresije protoonkogena HER2 kao 
značajnog prognostičkog faktora daljeg toka, ishoda bolesti i podatka za izbor adekvatne 
terapije. 
Istraživanje je urađeno kao prospektivna, kliničko-eksperimentalna studija. Korišćen 
je postoperativni materijal dobijen resekcijom kolorektalnog karcinoma od 63 bolesnika 
oba pola.  
Pozitivan HER2 status bio je u 9.5% tumora. Dobijeni rezultati pokazali su da se 
najveći broj tumora 36/63, tj. 57.1% manifestovao u vidu infiltrativne forme, 9/63, tj. 
14.3% kao ulcerišuća forma, a 18/63, tj. 28.6% tumora imalo je polipoidni – egzofitičan 
izgled. Rezultati su pokazali da je 31 tumor infiltrativne forme bio HER2 negativan a 5 ih 
je bilo HER2 pozitivno. Kod tumora ulcerišuće forme 9 je bilo HER2 negativno, a nije bilo 
pozitivnih HER2 tumora. Kod tumora vegetativne forme 17 je bilo HER2 negativno, a 
samo 1 je bio HER2 pozitivan. 
Ekspresija HER2 je izostala u 90,5% tumora i ne korelira sa makroskopskim 
izgledom i načinom rasta tumora. Nivo ekspresije HER2 nema dijagnostički, prediktivni i 
prognostički potencijal, dok je neosporna njegova važnost u razumevanju onkogeneze. 
Acta Medica Medianae 2011;50(4):5-10. 
 
Ključne reči: kolorektalni karcinom, HER 2, korelacija, makroskopski izgled, način 
rasta 